-
In March 2024, Allergan Aesthetics, an AbbVie company, announced the U.S. FDA approval of JUVÉDERM VOLUMA XC for the improvement of moderate to severe temple hollowing in adults over the age of 21. This marks it as the first and only hyaluronic acid (HA) dermal filler to receive FDA approval for this specific indication
- In February 2025 (news released about May 2025 launch), Evolus announced U.S. FDA approval for Evolysse Form and Evolysse Smooth injectable hyaluronic acid gels. These are the first two products in the Evolysse collection, marking Evolus' entry into the U.S. HA dermal filler market
- In April 2023, Croma-Pharma introduced PhilArt, a complete series of injectable skin boosters comprising long-chain polynucleotides (PN). These products are designed to improve skin quality, enhance radiance, restore elasticity, and promote hydration
- In March 2024, IBSA launched its new range of Aliaxin Dermal Fillers and Profhilo Body during the IBSA NEOASIA Gala Award. This showcases IBSA's continuous expansion of its medical aesthetics portfolio with innovative solutions for skin laxity and remodeling
- In June 2023, Galderma received U.S. FDA approval for Restylane Eyelight (Hyaluronic Acid Filler) for the treatment of undereye hollows in adults over the age of 21. This approval offers a new, effective solution for patients seeking to reduce the appearance of tired-looking eyes
